Company intelligence / Profile preview

Pharmapotheca A

Delmar, New York, United Statespharmapotheca.com ↗

Ownership: Private
Development stage: Other

Overview

Pharmapotheca A is developing novel small molecule compounds for the manufacture of amphetamines used in the treatment of ADHD. The company holds multiple US patents for its proprietary chemical processes and compounds. No clinical trial results are publicly available as of now; the company appears to be at a preclinical or prototype-ready stage[1][5].

Therapeutic areas: Psychiatry
Modalities: Small molecule (specifically dialkyl/diaryl(2-alkylaziridin-1-yl)phosphoramidate compounds)
Industry: Chemicals & Materials

Partnerships

Kinentia Biosciences (for laboratory sample distribution)

Beyond the preview

Go deeper on Pharmapotheca A.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmapotheca A.

Explore the full profile